Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues

Yu Mi Ahn, Lakshminarayana Vogeti, Chun Jing Liu, Hari K.R. Santhapuram, Jonathan M. White, Veena Vasandani, Lester A. Mitscher, Gerald H. Lushington, Paul R. Hanson, Douglas R. Powell, Richard H. Himes, Katherine F. Roby, Qizhuang Ye, Gunda I. Georg

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


The design and synthesis of a small library of 8-amidoflavone, 8-sulfonamidoflavone, 8-amido-7-hydroxyflavone, and heterocyclic analogues of flavopiridol is reported. The potential activity of these compounds as kinase inhibitors was evaluated by cytotoxicity studies in MCF-7 and ID-8 cancer cell lines and inhibition of CDK2-Cyclin A enzyme activity in vitro. The antiproliferative and CDK2-Cyclin A inhibitory activity of these analogues was significantly lower than the activity of flavopiridol. Molecular docking simulations were carried out and these studies suggested a different binding orientation inside the CDK2 binding pocket for these analogues compared to flavopiridol.

Original languageEnglish (US)
Pages (from-to)702-713
Number of pages12
JournalBioorganic and Medicinal Chemistry
Issue number2
StatePublished - Jan 15 2007

Bibliographical note

Funding Information:
This investigation was supported by NIH-COBRE award 1 P20 RR15563 (NIH-NCRR) with matching support from the State of Kansas and the University of Kansas. The authors thank Dr. David Vander Velde and Sarah Neuenswander for the assistance with the NMR measurements, Dr. Todd Williams for HRMS analysis, and Jacquelyn K. Huff for technical assistance. The authors also thank the National Science Foundation (Grant CHE-0079282) and the University of Kansas for funds to purchase the X-ray instrument and computers.


  • CDK2-Cyclin A
  • Cytotoxicity
  • Docking simulations
  • Flavopiridol analogues
  • Synthesis


Dive into the research topics of 'Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues'. Together they form a unique fingerprint.

Cite this